NASDAQ$TRML
Tourmaline Bio Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the quarter and year ended December 31, 2021.
Talaris Therapeutics reported a net loss of $14.2 million for Q4 2021 and finished the quarter with $244 million in cash, cash equivalents and marketable securities. The company continues to advance its clinical programs, including the Phase 3 FREEDOM-1 trial and the newly initiated Phase 2 FREEDOM-2 and FREEDOM-3 trials.
- Presented initial positive data update from the ongoing Phase 3 (FREEDOM-1) clinical trial of FCR001 in LDKT.
- Presented confirmatory data analysis from the Phase 2 trial demonstrating FCR001 induced durable tolerance in highly mismatched related and unrelated recipients with living donor kidney transplant (LDKT).
- Initiated Phase 2 (FREEDOM-3) clinical trial of FCR001 in scleroderma, its first severe autoimmune disease.
- Talaris finished Q4 2021 with $244.0 million in cash, cash equivalents and marketable securities.
Headline financials
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$0
Forward guidance
Talaris is advancing its clinical programs and anticipates providing additional updates on FREEDOM-1 in 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro